MMPs, especially MMP‐2 and MMP‐9, are highly expressed in pathological tissues derived from patients with metastatic HCC after SIRT treatment.40 In recent years, patients with metastatic HCC have been treated with personalized management and tailored therapy.41, 42, 43 GP73 might be a potential target in tailored therapy targeting metastatic HCC. The gene discussed is MMP9; the disease is hepatocellular carcinoma.